Home / Combinations / MOTS-c + SS-31
CombinationAnti-AgingFat LossEmerging evidence
MOTS-c + SS-31
Mitochondrial Optimization
A mitochondrial-targeted combination pairing two peptides with distinct but complementary mechanisms. MOTS-c enhances glucose metabolism and AMPK signaling while SS-31 (Elamipretide) stabilizes cardiolipin in the inner mitochondrial membrane, protecting against oxidative damage. Researched in contexts of aging, metabolic dysfunction, and exercise performance.
Stack components
MOTS-cCompound 01
SS-31Compound 02
2
Compounds
3
Sources on file
18
Providers carry all
Mechanism
What each compound is researched for on its own. Nothing here describes an interaction between them.
Compound 01
MOTS-c
Mitochondria-derived signaling peptide that activates AMPK and enhances glucose uptake. Multiple studies demonstrate improved exercise capacity and metabolic health in aged models.
Compound 02
SS-31
Targets cardiolipin in the inner mitochondrial membrane, reducing ROS production at the source. Phase 2/3 trials for mitochondrial myopathy and heart failure.
Composition
2 compounds · 2 research areas
Stated as recorded. This page describes each compound separately and makes no claim that they act together.
Safety notes
MOTS-c is a mitochondria-derived peptide studied primarily in preclinical models; human clinical data is very limited. SS-31 (elamipretide) is an investigational drug currently in Phase 2/3 clinical trials for Barth syndrome and heart failure — it is not approved for any indication. Neither compound is approved for general health or anti-aging use. Long-term safety profiles for both are still being established through ongoing clinical research.
Author-written. Not derived from any compound field, and not covered by the profile-integrity audit that gates the peptide pages.
Research references3 sources
Strong
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Cell Metab 2015
Strong
First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics
Br J Pharmacol 2014
Strong
Coordinated deficiency of complex I subunits in aging context
J Gerontol A Biol Sci Med Sci 2020
Related combinations3 share an area
Educational use only
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 19 Apr 2026.
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 19 Apr 2026.